​

Exelixis (EXEL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EXEL Stock Forecast

Exelixis (EXEL) stock forecast, based on 33 Wall Street analysts, predicts a 12-month average price target of $53.00, with a high of $60.00 and a low of $49.00. This represents a -19.94% decline from the last price of $66.20.

$35 $42 $49 $56 $63 $70 High: $60 Avg: $53 Low: $49 Last Closed Price: $66.2

EXEL Stock Rating

Exelixis stock's rating consensus is Hold, based on 33 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 16 Buy (48.48%), 17 Hold (51.52%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 33 0 17 16 Strong Sell Sell Hold Buy Strong Buy

EXEL Price Target Upside V Benchmarks

TypeNameUpside
StockExelixis-19.94%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3727
Avg Price Target$52.00$52.71$49.07
Last Closing Price$66.20$66.20$66.20
Upside/Downside-21.45%-20.38%-25.88%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 261610-118
Sep, 261612-120
Aug, 261710-119
Jul, 261710-119
Jun, 26199-120
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 30, 2026David LebowitzBMO Capital$60.00$66.20-9.37%-9.37%
Oct 09, 2026RBC Capital$51.00$59.77-14.67%-22.96%
Oct 08, 2026RBC Capital$45.00$58.10-22.55%-32.02%
Aug 18, 2026BMO Capital$54.00$53.121.66%-18.43%
Aug 06, 2026Andrew BerensLeerink Partners$52.00$52.59-1.12%-21.45%
Aug 06, 2026Gregory RenzaTruist Financial$52.00$54.54-4.66%-21.45%
Aug 03, 2026UBS$55.00$53.033.71%-16.92%
Jul 23, 2026Sean LaamanMorgan Stanley$53.00$54.99-3.62%-19.94%
Jul 14, 2026Etzer DaroutBarclays$49.00$56.04-12.56%-25.98%
Jul 13, 2026Wells Fargo$49.00$56.50-13.27%-25.98%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 30, 2026BMO CapitalMarket PerformMarket Performhold
Oct 19, 2026CitigroupOutperformOutperformhold
Oct 19, 2026CitigroupMarket OutperformMarket Outperformhold
Oct 09, 2026RBC CapitalSector PerformSector Performhold
Sep 14, 2026CitigroupMarket OutperformMarket Outperformhold
Sep 11, 2026William BlairOutperformOutperformhold
Aug 18, 2026BMO CapitalMarket PerformMarket Performinitialise
Jul 22, 2026CitigroupMarket OutperformMarket Outperformhold
Jul 07, 2026RBC CapitalSector PerformSector Performhold
Jul 02, 2026UBSNeutralNeutralhold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.73$0.57$0.65$1.80$2.88---
Avg Forecast$0.48$0.56$0.62$1.73$1.91$2.31$2.95$3.70
High Forecast$0.51$0.61$0.67$1.87$2.23$3.03$4.31$4.14
Low Forecast$0.45$0.53$0.49$1.55$1.57$1.20$1.26$3.49
Surprise %52.08%1.79%4.84%4.05%50.79%---

Revenue Forecast

$1B $2B $2B $3B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.43B$1.61B$1.83B$2.17B$2.32B---
Avg Forecast$1.34B$1.60B$1.83B$2.16B$2.23B$2.47B$2.76B$3.10B
High Forecast$1.40B$1.71B$1.87B$2.17B$2.46B$2.48B$2.77B$3.38B
Low Forecast$1.28B$1.52B$1.82B$2.15B$2.15B$2.46B$2.74B$2.96B
Surprise %7.20%0.48%-0.08%0.19%3.86%---

Net Income Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$231.06M$182.28M$207.76M$521.27M$782.57M---
Avg Forecast$584.15M$677.63M$207.76M$549.48M$552.48M$682.27M$877.02M$1.19B
High Forecast$700.98M$813.16M$249.32M$600.20M$716.83M$974.37M$1.38B$1.33B
Low Forecast$467.32M$542.11M$166.21M$498.76M$504.33M$387.25M$406.53M$1.12B
Surprise %-60.44%-73.10%--5.13%41.65%---

EXEL Forecast FAQ

Is Exelixis stock a buy?

Exelixis stock has a consensus rating of Hold, based on 33 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 16 Buy, 17 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Exelixis is a neutral investment for most analysts.

What is Exelixis's price target?

Exelixis's price target, set by 33 Wall Street analysts, averages $53 over the next 12 months. The price target range spans from $49 at the low end to $60 at the high end, suggesting a potential -19.94% change from the previous closing price of $66.2.

How does Exelixis stock forecast compare to its benchmarks?

Exelixis's stock forecast shows a -19.94% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Exelixis over the past three months?

  • October 2026: 5.56% Strong Buy, 33.33% Buy, 55.56% Hold, 0% Sell, 5.56% Strong Sell.
  • September 2026: 5.00% Strong Buy, 30.00% Buy, 60.00% Hold, 0% Sell, 5.00% Strong Sell.
  • August 2026: 5.26% Strong Buy, 36.84% Buy, 52.63% Hold, 0% Sell, 5.26% Strong Sell.

What is Exelixis’s EPS forecast?

Exelixis's average annual EPS forecast for its fiscal year ending in December 2026 is $2.31, marking a -19.79% decrease from the reported $2.88 in 2025. Estimates for the following years are $2.95 in 2027, and $3.7 in 2028.

What is Exelixis’s revenue forecast?

Exelixis's average annual revenue forecast for its fiscal year ending in December 2026 is $2.47B, reflecting a 6.48% increase from the reported $2.32B in 2025. The forecast for 2027 is $2.76B, and $3.1B for 2028.

What is Exelixis’s net income forecast?

Exelixis's net income forecast for the fiscal year ending in December 2026 stands at $682.27M, representing a -12.82% decrease from the reported $782.57M in 2025. Projections indicate $877.02M in 2027, and $1.19B in 2028.